Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MRSN

Mersana Therapeutics Inc

Dec 26 • 02:51PM ET

1.39

Dollar change -0.23
Percentage change -13.89	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN ALNY EXEL SRPT NBIX SAVA BPMC AGIO IMMP

| Held by: VTI IWM VXF VTWO IBB IWO IWN IWC ITOT FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	29.93%	Shs Outstand	122.87M	Perf Week	-17.46%
Market Cap	172.33M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	-0.29%	Shs Float	86.56M	Perf Month	-30.25%
Income	-74.62M	PEG	-	EPS next Q	-0.15	Inst Own	59.58%	Short Float	10.29%	Perf Quarter	-24.59%
Sales	34.84M	P/S	4.95	EPS this Y	60.21%	Inst Trans	-0.70%	Short Ratio	8.11	Perf Half Y	-30.08%
Book/sh	0.01	P/B	163.35	EPS next Y	3.99%	ROA	-34.51%	Short Interest	8.91M	Perf Year	-36.01%
Cash/sh	1.26	P/C	1.11	EPS next 5Y	-	ROE	-280.29%	52W Range	1.22 - 6.28	Perf YTD	-39.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.93%	ROI	-430.25%	52W High	-77.79%	Beta	1.36
Dividend TTM	-	Quick Ratio	2.35	Sales past 5Y	12371.94%	Gross Margin	95.19%	52W Low	14.34%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	2.35	EPS Y/Y TTM	65.61%	Oper. Margin	-228.07%	RSI (14)	31.86	Volatility	13.55% 12.09%
Employees	123	Debt/Eq	30.00	Sales Y/Y TTM	-14.70%	Profit Margin	-214.19%	Recom	1.40	Target Price	6.50
Option/Short	Yes / Yes	LT Debt/Eq	15.51	EPS Q/Q	72.89%	Payout	-	Rel Volume	1.42	Prev Close	1.62
Sales Surprise	67.35%	EPS Surprise	47.58%	Sales Q/Q	63.65%	Earnings	Nov 13 BMO	Avg Volume	1.10M	Price	1.39
SMA20	-33.72%	SMA50	-34.29%	SMA200	-41.95%	Trades		Volume	1,295,406	Change	-13.89%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-24	Resumed	Citigroup	Buy	$5
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral	$5
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform	$2 → $7
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy	$7
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy	$6
Dec-04-23	Upgrade	Citigroup	Neutral → Buy	$1 → $5
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral	$7 → $1
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral	$11 → $5
Jun-15-23	Initiated	Guggenheim	Buy	$14
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight	$10
Jan-20-23	Initiated	Citigroup	Buy	$12
Nov-21-22	Initiated	Truist	Buy	$12
Oct-15-21	Resumed	BTIG Research	Buy	$32
Aug-30-21	Initiated	H.C. Wainwright	Buy	$28

Show Previous Ratings

Nov-14-24 02:06AM	Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
01:32AM	Q3 2024 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-24 08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +19.55%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 08:00AM	Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 (GlobeNewswire) +16.42%
11:01AM	Loading…
Oct-15-24 11:01AM	SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc (GuruFocus.com)
Aug-13-24 08:20AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 08:00AM	Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024 (GlobeNewswire)
May-22-24 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-10-24 04:36PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.94%
03:15PM	Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
May-09-24 11:55AM	MRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -27.50%
08:05AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:59AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
04:30PM	Loading…
May-03-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024 (GlobeNewswire)
Apr-04-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-29-24 08:41AM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.16%
Feb-28-24 09:49PM	Q4 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.58%
08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:35AM	Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 08:01AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.17%
Feb-21-24 08:00AM	Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024 (GlobeNewswire)
Feb-20-24 10:00AM	Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-01-24 08:00AM	Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +6.96%
Jan-05-24 08:01AM	Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-23 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15% +7.37%
Nov-08-23 02:42PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:13AM	Loading…
12:13AM	Q3 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:10AM	Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 04:30PM	Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023 (GlobeNewswire) +7.21%
08:00AM	Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056 (GlobeNewswire)
Sep-07-23 06:30AM	The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure (American City Business Journals)
Sep-06-23 07:00AM	Mersana Therapeutics Announces Changes in Leadership (GlobeNewswire) +7.89%
Aug-18-23 09:35AM	After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN) (Zacks)
Aug-16-23 09:35AM	Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround (Zacks) -6.35%
Aug-08-23 09:40AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Mersana Therapeutics Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.24%
Jul-28-23 10:13AM	Block upgraded, Southwest downgraded: Wall Street's top analyst calls (The Fly) +17.76%
03:14AM	4 big analyst cuts: Snap slashed to Hold, Southwest gets several downgrades (Investing.com)
Jul-27-23 09:34PM	EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc (GuruFocus.com) -72.63%
01:44PM	Mersana slashes half its staff, loses $400M in value after trial failure (American City Business Journals)
07:06AM	Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization (GlobeNewswire)
Jul-13-23 09:45AM	15 Best Penny Stocks To Buy Now (Insider Monkey)
Jul-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-16-23 10:43AM	Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold (Zacks) -10.80%
02:26AM	5 big analyst cuts: SoFi Technologies slashed with 3 downgrades, shares plunge (Investing.com)
Jun-15-23 09:32AM	Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser (Motley Fool) -59.27%
07:36AM	US FDA puts Mersana Therapeutics's ovarian cancer study on hold (Reuters)
07:30AM	Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials (GlobeNewswire)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +5.45%
Jun-02-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.82%
May-28-23 09:06AM	Those who invested in Mersana Therapeutics (NASDAQ:MRSN) a year ago are up 127% (Simply Wall St.)
May-24-23 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-23 08:35AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.82%
07:00AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.00%
May-03-23 08:00AM	Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire) +46.12%
May-02-23 08:00AM	Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023 (GlobeNewswire) -7.01%
Apr-26-23 04:05PM	Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-17-23 11:07AM	Getting In Cheap On Mersana Therapeutics, Inc. (NASDAQ:MRSN) Is Unlikely (Simply Wall St.) +5.54%
Apr-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-05-23 02:00PM	J.P. Morgan Suggests 2 Stocks to Buy, Including One With 140% Upside Potential (TipRanks)
Mar-16-23 11:20AM	Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More (Zacks) +6.37%
Mar-13-23 02:00PM	FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death (Benzinga)
07:54AM	UPDATE 1-U.S. FDA places Mersana's cancer drug trial on hold following death (Reuters)
07:30AM	Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial (GlobeNewswire)
Mar-10-23 07:10PM	Mersana Therapeutics Provides Statement About SVB (GlobeNewswire) -12.00%
Mar-03-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.53%
Mar-02-23 08:55PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 05:24AM	Mersana Therapeutics Full Year 2022 Earnings: US$2.18 loss per share (vs US$2.41 loss in FY 2021) (Simply Wall St.)
Feb-28-23 11:51PM	Q4 2022 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.60%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-21-23 08:00AM	Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023 (GlobeNewswire)
Feb-03-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-23 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-01-23 08:00AM	Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer (GlobeNewswire)
Jan-25-23 08:00AM	Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors (GlobeNewswire)
Jan-20-23 03:16PM	With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics (Benzinga) +9.97%
Jan-16-23 02:18AM	Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones (GlobeNewswire)
Dec-31-22 07:42AM	Estimating The Fair Value Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) (Simply Wall St.)
Dec-23-22 12:46PM	Merck KGaA inks deal worth up to $830M with Cambridge cancer biotech (American City Business Journals)
10:08AM	Mersana Inks Cancer Therapy Development Deal With Merck Germany (Benzinga)
Dec-22-22 04:08PM	Mersana signs deal with Merck KGaA for cancer therapy development (Reuters)
04:05PM	Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates (GlobeNewswire)
Dec-14-22 08:00AM	European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer (GlobeNewswire)
Dec-02-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.09%
Nov-08-22 08:00AM	Mersana Therapeutics to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-22 08:25AM	Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -11.94%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-22 08:00AM	Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022 (GlobeNewswire) +9.47%

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bala Mohan	SVP, Chief Development Officer	Oct 25 '24	Option Exercise	0.00	6,250	0	56,615	Oct 29 04:43 PM
Bala Mohan	SVP, Chief Development Officer	Oct 28 '24	Sale	1.90	1,884	3,580	54,731	Oct 29 04:43 PM
Bala, Mohan	Officer	Oct 28 '24	Proposed Sale	2.04	1,884	3,843		Oct 29 04:26 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 01 '24	Option Exercise	0.00	50,000	0	108,511	Oct 07 05:48 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 02 '24	Sale	2.00	8,089	16,178	100,422	Oct 07 05:48 PM
DeSchuytner Brian	SVP, COO & CFO	Oct 03 '24	Sale	1.96	5,598	10,972	94,824	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	77,403	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 02 '24	Sale	2.00	8,089	16,178	69,314	Oct 07 05:48 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Oct 03 '24	Sale	1.96	5,598	10,972	63,716	Oct 07 05:48 PM
Bala Mohan	SVP, Chief Development Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	64,052	Oct 07 05:47 PM
Bala Mohan	SVP, Chief Development Officer	Oct 02 '24	Sale	2.00	8,089	16,178	55,963	Oct 07 05:47 PM
Bala Mohan	SVP, Chief Development Officer	Oct 03 '24	Sale	1.96	5,598	10,972	50,365	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 01 '24	Option Exercise	0.00	30,000	0	55,973	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 02 '24	Sale	2.00	4,855	9,710	51,118	Oct 07 05:47 PM
Mandelia Ashish	VP, Chief Accounting Officer	Oct 03 '24	Sale	1.96	3,361	6,588	47,757	Oct 07 05:47 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 01 '24	Option Exercise	0.00	50,000	0	249,329	Oct 07 05:46 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 02 '24	Sale	2.00	8,089	16,178	241,240	Oct 07 05:46 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Oct 03 '24	Sale	1.96	5,598	10,972	235,642	Oct 07 05:46 PM
Bala, Mohan	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:20 PM
Carvajal, Alejandra	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:19 PM
Brian DeSchuytner	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:18 PM
Timothy B. Lowinger	Officer	Oct 02 '24	Proposed Sale	2.02	8,089	16,340		Oct 07 05:18 PM
Huber Martin H. Jr.	President, CEO	Sep 11 '24	Option Exercise	0.00	166,750	0	166,750	Sep 13 05:08 PM
Huber Martin H. Jr.	President, CEO	Sep 12 '24	Sale	1.76	50,423	88,744	116,327	Sep 13 05:08 PM
Huber, Martin H. Jr.	Officer, Director	Sep 12 '24	Proposed Sale	1.77	50,423	89,249		Sep 13 05:06 PM
Protopapas Anna	Director	Jan 15 '24	Option Exercise	0.00	38,958	0	154,552	Jan 17 05:21 PM
Protopapas Anna	Director	Jan 14 '24	Option Exercise	0.00	16,750	0	115,594	Jan 17 05:21 PM
Protopapas Anna	Director	Jan 13 '24	Option Exercise	0.00	31,250	0	98,844	Jan 17 05:21 PM
Protopapas Anna	Director	Jan 16 '24	Sale	2.71	29,399	79,671	125,153	Jan 17 05:21 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 14 '24	Option Exercise	0.00	1,458	0	21,323	Jan 17 05:21 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 13 '24	Option Exercise	0.00	7,083	0	19,865	Jan 17 05:21 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 16 '24	Sale	2.71	3,357	9,097	17,966	Jan 17 05:21 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 15 '24	Option Exercise	0.00	5,352	0	28,353	Jan 17 05:20 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 14 '24	Option Exercise	0.00	4,783	0	23,001	Jan 17 05:20 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 13 '24	Option Exercise	0.00	2,645	0	18,218	Jan 17 05:20 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 16 '24	Sale	2.71	5,025	13,618	23,328	Jan 17 05:20 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 15 '24	Option Exercise	0.00	15,208	0	209,738	Jan 17 05:19 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 14 '24	Option Exercise	0.00	4,792	0	194,530	Jan 17 05:19 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 13 '24	Option Exercise	0.00	9,375	0	189,738	Jan 17 05:19 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 16 '24	Sale	2.71	10,409	28,208	199,329	Jan 17 05:19 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 14 '24	Option Exercise	0.00	2,500	0	31,784	Jan 17 05:18 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 13 '24	Option Exercise	0.00	8,958	0	29,284	Jan 17 05:18 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 16 '24	Sale	2.71	4,381	11,873	27,403	Jan 17 05:18 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 15 '24	Option Exercise	0.00	10,208	0	63,838	Jan 17 05:18 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 14 '24	Option Exercise	0.00	6,250	0	55,630	Jan 17 05:18 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 13 '24	Option Exercise	0.00	10,000	0	47,380	Jan 17 05:18 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 16 '24	Sale	2.71	9,327	25,276	54,511	Jan 17 05:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 13 '24	Option Exercise	0.00	8,750	0	17,483	Jan 17 05:16 PM
Bala Mohan	SVP, Chief Development Officer	Jan 16 '24	Sale	2.71	3,431	9,298	14,052	Jan 17 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRSN

Mersana Therapeutics Inc

Upgrade your FINVIZ experience